Renaissance Technologies
RARE icon

Renaissance Technologies’s Ultragenyx Pharmaceutical RARE Stock Holding History

Renaissance Technologies’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.8M Sell
413,700
-148,000
-26% -$3.68M 0.02% 889
2026
Q1 		$11.8M Buy
561,700
+195,600
+53% +$4.4M 0.02% 887
2025
Q4 		$8.42M Buy
366,100
+344,200
+1,572% +$11.3M 0.01% 1008
2025
Q3 		$659K Sell
21,900
-186,400
-89% -$5.59M ﹤0.01% 2683
2025
Q2 		$7.57M Sell
208,300
-91,300
-30% -$3.29M 0.01% 1258
2025
Q1 		$10.8M Buy
299,600
+44,900
+18% +$1.87M 0.02% 967
2024
Q4 		$10.7M Buy
254,700
+72,600
+40% +$3.6M 0.02% 979
2024
Q3 		$10.1M Buy
+182,100
New +$9.28M 0.02% 1030
2023
Q3 		– Sell
-19,600
Closed -$904K – 4023
2023
Q2 		$904K Buy
+19,600
New +$909K ﹤0.01% 2532
2022
Q1 		– Sell
-47,400
Closed -$3.99M – 4388
2021
Q4 		$3.99M Sell
47,400
-24,200
-34% -$1.97M 0.01% 1668
2021
Q3 		$6.46M Sell
71,600
-390,800
-85% -$35.3M 0.01% 1307
2021
Q2 		$44.1M Buy
462,400
+317,600
+219% +$33.1M 0.06% 376
2021
Q1 		$16.5M Buy
144,800
+50,000
+53% +$6.81M 0.02% 892
2020
Q4 		$13.1M Buy
+94,800
New +$11.2M 0.01% 989
2016
Q2 		– Sell
-54,400
Closed -$3.44M – 3477
2016
Q1 		$3.44M Buy
+54,400
New +$3.56M 0.01% 1895
2015
Q4 		– Sell
-3,200
Closed -$308K – 3401
2015
Q3 		$308K Buy
+3,200
New +$366K ﹤0.01% 2761

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Renaissance Technologies's RARE Position: Q2 2026 in Review

Renaissance Technologies reduced its Ultragenyx Pharmaceutical (RARE) stake by 26% in Q2 2026, selling an estimated $3.68M and leaving 413,700 shares worth $13.8M. The position accounts for 0.02% of the portfolio, ranked #889.

Renaissance Technologies first reported a position in RARE in Q3 2015 and has held it in 16 quarters since. The position peaked at $44.1M in Q2 2021. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Renaissance Technologies held 413,700 shares of Ultragenyx Pharmaceutical worth $13.8M as of Q2 2026.
  • Renaissance Technologies sold 148,000 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $3.68M.
  • Ultragenyx Pharmaceutical made up 0.02% of Renaissance Technologies's portfolio in Q2 2026, its #889 holding.
  • Renaissance Technologies first reported a position in Ultragenyx Pharmaceutical in Q3 2015 and has held it in 16 quarters since.
  • Renaissance Technologies's Ultragenyx Pharmaceutical position peaked at $44.1M in Q2 2021.
  • 310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.